Insights into the Future of Gastric Acid Suppression

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2009 Aug 29

PMID 19713987

Citations 24

Authors

Kenneth R DeVault

Nicholas J Talley

Affiliations

Soon will be listed here.

Abstract

The development of effective acid-suppression therapy (particularly PPIs) has revolutionized the treatment of acid-related diseases. Despite the overall effectiveness of these agents, they have some shortcomings, including a delayed onset of action, incomplete acid suppression in the majority of patients, and the need for ingestion before a meal to achieve maximal efficacy. Attempts to overcome these issues have included the development of isomeric PPIs (such as esomeprazole), alterations in drug delivery (such as delayed-release dexlansoprazole), and combined therapy with nonenterically coated PPIs and antacids (such as 'naked' omeprazole combined with sodium biocarbonate). Other acid-suppression agents in development or in late-phase trials include potassium-competitive acid blockers, new histamine receptor 2 antagonists, and gastrin antagonists. Although these agents could potentially achieve complete gastric acid suppression, risks may be associated with this level of suppression, including enteric infections and malabsorption of nutrients such as vitamin B(12), iron and calcium. This Review provides an update on the status of acid-suppression therapy and discusses directions for future research.

Citing Articles

Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection.

Park C, Park J, Jung Y Clin Transl Gastroenterol. 2023; 14(11):e00632.

PMID: 37561041 PMC: 10684139. DOI: 10.14309/ctg.0000000000000632.

A survey on the incidence of common musculoskeletal side effects among the patients taking long-term anti-ulcerant therapies in Bangladesh.

Mitra S, Hussain M, Rahman R, Salam M, Mazumder T, Farzana S Toxicol Rep. 2022; 9:1796-1805.

PMID: 36518456 PMC: 9742954. DOI: 10.1016/j.toxrep.2022.09.007.

Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of : A Real-World Evidence Study.

Jung Y, Kim S, Kim H, Noh S, Park J, Sohn C Gut Liver. 2022; 17(5):711-721.

PMID: 36510776 PMC: 10502490. DOI: 10.5009/gnl220218.

Atazanavir-Concentrate Loaded Soft Gelatin Capsule for Enhanced Concentration in Plasma, Brain, Spleen, and Lymphatics.

Sethi S, Rana V AAPS PharmSciTech. 2022; 23(7):270.

PMID: 36171353 DOI: 10.1208/s12249-022-02428-0.

Anti-Inflammatory Effect of on Ethanol-Induced Gastric Ulcer: Analytical, In Vitro and In Vivo Studies for the Identification of Action Mechanism and Active Compounds.

Shin M, Lee J, Lee J, Park S, Lee I, Choi J Plants (Basel). 2021; 10(2).

PMID: 33572173 PMC: 7914715. DOI: 10.3390/plants10020332.

References

Laheij R, Sturkenboom M, Hassing R, Dieleman J, Stricker B, Jansen J . Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004; 292(16):1955-60. DOI: 10.1001/jama.292.16.1955. View

Chowdhury J, Berkowitz J, Praissman M, Fara J . Effect of sulfated and non-sulfated gastrin and octapeptide-cholecystokinin on cat gall bladder in vitro. Experientia. 1976; 32(9):1173-5. DOI: 10.1007/BF01927609. View

Malfertheiner P, Megraud F, OMorain C, Bazzoli F, El-Omar E, Graham D . Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2006; 56(6):772-81. PMC: 1954853. DOI: 10.1136/gut.2006.101634. View

Kim K, Shon J, Park J, Yoon Y, Kim M, Yun D . Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin Pharmacol Ther. 2002; 72(1):90-9. DOI: 10.1067/mcp.2002.126176. View

Castell D, Bagin R, Goldlust B, Major J, Hepburn B . Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005; 21(12):1467-74. DOI: 10.1111/j.1365-2036.2005.02513.x. View

Erah P, Goddard A, Barrett D, Shaw P, Spiller R . The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997; 39(1):5-12. DOI: 10.1093/jac/39.1.5. View

Recker R . Calcium absorption and achlorhydria. N Engl J Med. 1985; 313(2):70-3. DOI: 10.1056/NEJM198507113130202. View

Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E . Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2003; (4):CD002296. DOI: 10.1002/14651858.CD002296. View

Gustavson L, Kaiser J, Edmonds A, Locke C, DeBartolo M, Schneck D . Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother. 1995; 39(9):2078-83. PMC: 162884. DOI: 10.1128/AAC.39.9.2078. View

10.

Pai V, Pai N . Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. World J Gastroenterol. 2007; 13(30):4100-2. PMC: 4205312. DOI: 10.3748/wjg.v13.i30.4100. View

11.

Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum A . Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003; 17(12):1507-14. DOI: 10.1046/j.1365-2036.2003.01496.x. View

12.

Hellstrom P, Vitols S . The choice of proton pump inhibitor: does it matter?. Basic Clin Pharmacol Toxicol. 2004; 94(3):106-11. DOI: 10.1111/j.1742-7843.2004.pto940302.x. View

13.

Iwase K, Evers B, Hellmich M, Guo Y, Higashide S, Kim H . Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin. Gastroenterology. 1997; 113(3):782-90. DOI: 10.1016/s0016-5085(97)70172-0. View

14.

Koop H, Bachem M . Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992; 14(4):288-92. DOI: 10.1097/00004836-199206000-00005. View

15.

Dunlop J . CCK receptor antagonists. Gen Pharmacol. 1998; 31(4):519-24. DOI: 10.1016/s0306-3623(98)00078-0. View

16.

Shin J, Homerin M, Domagala F, Ficheux H, Sachs G . Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo. Biochem Pharmacol. 2006; 71(6):837-49. DOI: 10.1016/j.bcp.2005.11.030. View

17.

Yang Y, Hennessy S, Propert K, Hwang W, Sedarat A, Lewis J . Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007; 133(3):748-54. DOI: 10.1053/j.gastro.2007.06.022. View

18.

Konturek P, Brzozowski T, Konturek S, Marquez M, Torres J, Ortiz J . Studies on the cytoprotective and antisecretory activity of ebrotidine. A review. Arzneimittelforschung. 1997; 47(4A):578-89. View

19.

Richter J, Kahrilas P, Johanson J, Maton P, Breiter J, Hwang C . Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001; 96(3):656-65. DOI: 10.1111/j.1572-0241.2001.3600_b.x. View

20.

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2008; 360(4):363-75. DOI: 10.1056/NEJMoa0808227. View